Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLL2: Pneumococcal vaccine (PPV) booster in CLL
NCT00919321Phase 4Completed
- Sponsor
- Tampere University Hospital
- Start
- Jun 2009
- Primary completion
- Dec 2013
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Tampere University Hospital. Primary endpoint: Antibody response at 12 weeks. Started Jun 2009; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00919321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00919321.